Tao Guo

Years Active: 2018-2019
Publications (10 Years): 3

WuXi AppTec

Columbia University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

WuXi AppTec Dec 01 2008

China

Vice Predident :: Research Service Division

Pharmacopeia Drug Discovery Inc Oct 01 1995 - Oct 30 2008

United States

Director :: Chemistry

Ariad Pharmaceuticals Inc Aug 15 1992 - Sep 30 1995

United States

Senior Scientist :: Chemistry

Education History

Columbia University Sep 01 1985 - Feb 10 1990

United States

PHD :: Chemistry

Peking University Sep 01 1980 - Jul 10 1984

China

BSC :: Chemistry

Publications

Xiufang Zheng, Lu Gao, Lisha Wang, Chungen Liang, Baoxia Wang, Yongfu Liu, Song Feng, Bo Zhang, Mingwei Zhou, Xin Yu, Kunlun Xiang, Li Chen, Tao Guo, Hong C Shen, Gang Zou, Jim Zhen Wu, Hongying Yun
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. Journal of medicinal chemistry 62 (13) (2019)
Alex Zhavoronkov, Yan A Ivanenkov, Alex Aliper, Mark S Veselov, Vladimir A Aladinskiy, Anastasiya V Aladinskaya, Victor A Terentiev, Daniil A Polykovskiy, Maksim D Kuznetsov, Arip Asadulaev, Yury Volkov, Artem Zholus, Rim R Shayakhmetov, Alexander Zhebrak, Lidiya I Minaeva, Bogdan A Zagribelnyy, Lennart H Lee, Richard Soll, David Madge, Li Xing, Tao Guo, Alán Aspuru-Guzik
Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature biotechnology 37 (9) (2019)
Xiufang Zheng, Chungen Liang, Lisha Wang, Baoxia Wang, Yongfu Liu, Song Feng, Jim Zhen Wu, Lu Gao, Lichun Feng, Li Chen, Tao Guo, Hong C Shen, Hongying Yun
Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors. Journal of medicinal chemistry 61 (22) (2018)

Tao Guo.css-eqlu8i{font-size:small;padding-left:4px;}